Showing 1681-1690 of 1945 results for "".
- Burnout Rises Above 50% in Some Specialties, New Survey Showshttps://modernod.com/news/burnout-rises-above-50-in-some-specialties-new-survey-shows/2476179/Responses to a new Medscape survey indicate that 44% of physicians meet the criteria for burnout, up from 42% in last year’s report. In addition, 11% are colloquially depressed (feeling down or sad), and 4% are clinically depressed, according to the
- Takeda CEO Optimistic About Growth Prospects as Drugmaker Finalizes Shire Takeoverhttps://modernod.com/news/takeda-ceo-optimistic-about-growth-prospects-as-drugmaker-finalizes-shire-takeover/2476205/Takeda announced that it has completed its $62-billion acquisition of Shire. Christophe Weber, chief executive of Takeda, stated “this marks a significant moment in [our] history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicin
- California Optometrists Caution Patients About Unapproved, Online Vision Tests After FDA Warninghttps://modernod.com/news/california-optometrists-caution-patients-about-unapproved-online-vision-tests-after-fda-warning/2480161/The California Optometric Association cautioned California consumers that self-administered “vision tests” conducted online come with significant safety concerns and appear to violate federal law, according to a news release. In a letter to the California Attorney General, the organization
- FDA Recall Prompts Nationwide Warning Over Millions of Eye Dropshttps://modernod.com/news/fda-recall-prompts-nationwide-warning-over-millions-of-eye-drops/2486525/Key Takeaways More than 3.1 million bottles of store-brand eye drops have been recalled nationwide due to concerns about product sterility
- AAO: Office-Based Cataract Surgery Study Shows Success With Minimal Oral Sedationhttps://modernod.com/news/aao-office-based-cataract-surgery-study-shows-success-with-minimal-oral-sedation/2484197/A new study presented at the 129th annual meeting of the American Academy of Ophthalmology (AAO) is challenging long-held assumptions about cataract surgery. The research demonstrates that patients can safely and successfully undergo office-based cataract surgery u
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut